Use of the short-acting insulin analogue lispro in intensive treatment of Type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal
Authors:
- 19 July 1998
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 15 (7) , 592-600
Abstract
To establish whether lispro may be a suitable short‐acting insulin preparation for meals in intensive treatment of Type 1 diabetes mellitus (DM) in patients already in chronic good glycaemic control with conventional insulins, 69 patients on intensive therapy (4 daily s.c. insulin injections, soluble at each meal, NPH at bedtime, HbA1c 1c and frequency of hypoglycaemia were assessed under four different conditions (Groups I–IV). Lispro was always injected at mealtime, soluble 10–40 min prior to meals (with the exception of Group IV). Bedtime NPH was continued with both treatments. When lispro replaced soluble with no increase in number of daily NPH injections (Group I, n = 15), HbA1c was no different (p = NS), but frequency of hypoglycaemia was greater (p < 0.05). When NPH was given 3–4 times daily, lispro (Group II, n = 18), but not soluble (Group III, n = 12) decreased HbA1c by 0.35 ± 0.25 % with no increase in hypoglycaemia. When soluble was injected at mealtimes, HbA1c increased by 0.18 ± 0.15% and hypoglycaemia was more frequent than when soluble was injected 10–40 min prior to meals (Group IV, n = 24) (p < 0.05). It is concluded that in intensive management of Type 1 DM, lispro is superior to soluble in terms of reduction of % HbA1c and frequency of hypoglycaemia, especially for those patients who do not use a time interval between insulin injection and meal. However, these goals cannot be achieved without optimization of basal insulin. © 1998 John Wiley & Sons, Ltd.Keywords
This publication has 10 references indexed in Scilit:
- Reduced Frequency of Severe Hypoglycemia and Coma in Well-Controlled IDDM Patients Treated With Insulin LisproDiabetes Care, 1997
- Metabolic Efficacy of Preprandial Administration of Lys(B28), Pro(B29) Human Insulin Analog in IDDM Patients: A comparison with human regular insulin during a three-meal test periodDiabetes Care, 1997
- Strategies Toward Improved Control During Insulin Lispro Therapy in IDDM: Importance of basal insulinDiabetes Care, 1997
- Insulin LisproNew England Journal of Medicine, 1997
- Insulin lispro in CSII: results of a double-blind crossover studyDiabetes, 1997
- Pre-meal Insulin Analogue Insulin Lispro vs Humulin® R Insulin Treatment in Young Subjects with Type 1 DiabetesDiabetic Medicine, 1996
- THE RELATIONSHIP OF GLYCEMIC EXPOSURE (HBA(1C)) TO THE RISK OF DEVELOPMENT AND PROGRESSION OF RETINOPATHY IN THE DIABETES CONTROL AND COMPLICATIONS TRIAL1995
- Nocturnal Blood Glucose Control in Type I Diabetes MellitusDiabetes Care, 1993
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993
- Interval between insulin injection and eating in relation to blood glucose control in adult diabetics.BMJ, 1985